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Abstract
Introduction
Randomised controlled trials have shown that targeted therapies like sunitinib are effective
in metastatic renal cell carcinoma (mRCC). Little is known about the current use of these
therapies, and their associated costs and effects in daily clinical practice. We estimated the
real-world cost-effectiveness of different treatment strategies comprising one or more
sequentially administered drugs.
Methods
Analyses were performed using patient-level data from a Dutch population-based registry
including patients diagnosed with primary mRCC from January 2008 to December 2010
(i.e., treated between 2008 and 2013). The full disease course of these patients was esti-
mated using a patient-level simulation model based on regression analyses of the registry
data. A healthcare sector perspective was adopted; total costs included healthcare costs
related to mRCC. Cost-effectiveness was expressed in cost per life-year and cost per qual-
ity-adjusted life-year (QALY) gained. Probabilistic sensitivity analysis was conducted to esti-
mate the overall uncertainty surrounding cost-effectiveness.
Results
In current daily practice, 54% (336/621) of all patients was treated with targeted therapies.
Most patients (84%; 282/336) received sunitinib as first-line therapy. Of the patients receiv-
ing first-line therapy, 30% (101/336) also received second-line therapy; the majority was
treated with everolimus (40%, 40/101) or sorafenib (28%, 28/101). Current treatment
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practice (including patients not receiving targeted therapy) led to 0.807 QALYs; mean costs
were €58,912. This resulted in an additional €105,011 per QALY gained compared to not
using targeted therapy at all. Forty-six percent of all patients received no targeted therapy;
of these patients, 24% (69/285) was eligible for sunitinib. If these patients were treated with
first-line sunitinib, mean QALYs would improve by 0.062–0.076 (where the range reflects
the choice of second-line therapy). This improvement is completely driven by the health gain
seen amongst patients eligible to receive sunitinib but did not receive it, who gain 0.558–
0.684 QALYs from sunitinib. Since additional costs would be €7,072–9,913, incremental
costs per QALY gained are €93,107–111,972 compared to current practice.
Discussion
Health can be gained if more treatment-eligible patients receive targeted therapies. More-
over, it will be just as cost-effective to treat these patients with sunitinib as current treatment
practice.
Introduction
Attention for the cost-effectiveness of cancer treatments is swiftly increasing, particularly
prompted by the advent of so-called molecularly targeted agents. This class of agents has
clearly improved outcomes in several tumor types, but also substantially increased costs.[1]
One of the tumor types for which targeted treatments are available is metastatic renal cell car-
cinoma (mRCC).
In 2008, there were an estimated 88,400 new cases of kidney cancer in Europe.[2] The Euro-
pean mean age-standardised 5-year survival was 60.6%, but substantial differences were seen
within European regions.[3] Besides registration artefacts, differences in cancer biology, the
use of diagnostic tests and screening, and access to high-quality care might explain the differ-
ences in cancer survival.[3]
While previous studies demonstrated a survival benefit from targeted therapies in meta-
static renal cell carcinoma,[4–8] a Dutch population-based registry showed that many treat-
ment-eligible patients do not receive sunitinib (or any other targeted therapy) in daily practice.
[9] This was also seen in England where one in three patients with mRCC eligible for either
sunitinib or pazopanib did not receive the drug.[10] Patient and disease characteristics might
play a role in the decision to not prescribe targeted therapy. Another possible reason is that it
is not cost-effective to treat these patients.
There is little known about the effect that the potential underuse of targeted therapy in daily
clinical practice has on health outcomes and costs. The aim of this study was to estimate the
real-world cost-effectiveness of several treatment strategies applied in patients with mRCC
comprising one or more sequentially administered drugs.
Patients and methods
Study population and data
From the Dutch Cancer Registry, all patients newly diagnosed with mRCC, i.e., metastatic dis-
ease at first presentation, from January 2008 until December 2010 in 42 hospitals (both general
and academic) in four regions, covering approximately half of The Netherlands, were included
in the PERCEPTION registry. In this registry, data on patient characteristics, treatment
A cost-effectiveness analysis in metastatic renal cell carcinoma
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schemes, treatment endpoints and resource use were retrospectively collected from patient
records. Data had been anonymised and de-identified prior to analyses, thus no written
informed consent was required. The research protocol was approved by the medical ethics
committee of Radboud university medical centre in Nijmegen (CMO Region Arnhem-Nijme-
gen) in May 2010.
Model structure and design
A patient-level simulation (PLS) model was developed to model the full disease course of
patients newly diagnosed with mRCC. The model comprised entities (i.e., patients), attributes
assigned to the entities, and events. Attributes were obtained from patient-level data from the
PERCEPTION registry by selecting clinical factors, biochemical and hematologic factors
known to impact mRCC outcomes.[11, 12] Events were either second-line treatment or death.
The time horizon of the model spanned the patients’ lifetime. The total structure of the model
is presented in S1 Fig.
Parameter estimation and time-to-event
For each patient in the PERCEPTION registry, time from diagnosis of mRCC until the first
event (TTE1) (i.e., second-line treatment or death) was calculated. Similarly, the time from
start of second-line treatment until the second event (TTE2) (i.e., death) was calculated.
We then compared a range of parametric models to extrapolate the survival data. The fit of
different models was assessed systematically by performing Akaike Information Criterion
(AIC) and Bayesian Information Criterion (BIC) tests. Additionally, visual inspection was per-
formed by comparing the parametric survival models with the Kaplan-Meier curves.
Clinical factors, biochemical and hematological factors, and the type of targeted treatment
were considered for inclusion in the models; TTE1 was also considered as a covariate to esti-
mate TTE2. Backward selection was used to select the attributes for the model; any non-signifi-
cant attributes (α = 0.10) were excluded from the model one at a time. Forward selection was
used to create an alternative model. When two different models were created, AIC and BIC
tests were performed, and visual inspection was used to decide on the final model.
Missing data were handled using multiple imputations by chained equations.[13] All statis-
tical analyses were conducted using Stata/SE 13.
Model calculation
Populations of 621 patients (i.e., the same sample size as the original study population) were
repeatedly simulated, one population at a time. Each simulation started with assigning patient
and disease characteristics to each patient, based on patient profiles observed in the PERCEP-
TION registry. That is, random numbers were drawn from predefined distributions for all
patient and disease characteristics; similar distributions were used for patients with a similar
WHO performance status. For example, the probability of having more than one metastatic
site was 64% for patients with a WHO performance status of 0–1, but 73% for patients with a
WHO performance status of 2–4. In addition, the previous measurement (e.g., number of met-
astatic sites before first-line treatment) was taken into account when simulating patient and
disease characteristics before second-line treatment.
The TTE1 for each simulated patient was determined by drawing random numbers from
two parametric survival models; that is, one model was used to calculate TTE1 until 12 months
while a second model was used to calculate TTE1 after 12 months. Two models were used
since the probability of an event (i.e., second-line treatment or death) from 12 months
onwards was underestimated when only one single model was used. The type of event
A cost-effectiveness analysis in metastatic renal cell carcinoma
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(i.e., second-line treatment or death) was determined using a separate model. The TTE2 was
calculated in a similar manner.
If a patient’s modelled time to an event was longer than the remaining life expectancy based
on national vital statistics data,[14] we used national vital statistics data to estimate TTE1 and
TTE2 because it is not plausible for someone with mRCC to have a longer than average life
expectancy.
Treatment scenarios
In the base-case scenario, patients were treated as they were in the real world (Fig 1). A multi-
nomial logistic regression model based on patient-level data from the PERCEPTION registry
was used to predict the type of treatment in both first- and second-line, using values for WHO
performance status, haemoglobin, corrected serum calcium and lactate dehydrogenase (i.e., 4/
5 Memorial Sloan Kettering Cancer Center (MSKCC) criteria).[15]
Alternative scenarios included no targeted therapy for all patients, or treating all patients
just as they were in reality, except for one difference, namely that first-line sunitinib followed
by sorafenib, everolimus or another second-line treatment was given to patients who did not
receive any targeted treatment even though they fulfilled the SUTENT trial eligibility criteria
(Fig 1). A patient was classified as fulfilling SUTENT trial eligibility criteria if he had a clear-
cell subtype, a WHO performance status of 0 or 1 and no brain metastases.[16]
The potential health outcomes and costs of all treatment scenarios were calculated by run-
ning the model for 621 simulated patients.
Health outcomes
Health outcomes were estimated in terms of life-years (LYs) and quality-adjusted life-years
(QALYs). QALYs were calculated by weighting LYs for the quality of life during these years
using utility weights derived from the published literature (S1 Table).[17–19]
Fig 1. First-line therapies in the various treatment scenarios.
https://doi.org/10.1371/journal.pone.0177364.g001
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Resource use and costs
This cost-effectiveness analysis (CEA) was conducted from a health care sector perspective,
but only included health care costs related to mRCC, i.e., drug costs as well as resource utilisa-
tion costs, such as hospitalisations, outpatient visits and medical imaging services. Hospitalisa-
tions due to adverse events were included while other types of costs due to adverse events,
such as concomitant medications, were not. The calculation of drug costs and resource utilisa-
tion costs is described in S1 Text.
Costs were reported in Euro 2014. Wherever necessary, costs were adjusted to 2014 using
the general price index derived from Statistics Netherlands.[20] Costs and effects were dis-
counted at 4% and 1.5%, respectively.[21]
Model validation
The model was internally validated by comparing patient characteristics and OS observed in
the PERCEPTION registry to patient characteristics and health outcomes according to the
model.[22] Health outcomes from the model were presented as the mean of 1000 iterations
with a 95% confidence interval (C.I.) using the standard deviation of 1000 iterations as stan-
dard error of the mean. The model’s internal validity was assessed by evaluating whether OS
observed in the PERCEPTION registry fell within the 95% C.I. of the OS according to the
base-case scenario of the model.
Sensitivity analysis
Univariate sensitivity analyses were performed to examine the impact of alternative input
parameters on the incremental cost-effectiveness ratios (ICERs). Probabilistic sensitivity analy-
sis (PSA) was conducted to examine the impact of the joint uncertainty regarding all input
parameters on the results.
Results
Study population and treatment
714 patients in the Dutch Cancer Registry fulfilled the inclusion criteria. 39 patients were
excluded (S2 Fig), and an additional 30 patients were lost to follow-up. Complete follow-up
up to three years after diagnosis was available for 645 patients. Twenty-four of these patients
received a metastasectomy (combined with a nephrectomy) with a possible curative inten-
tion, making targeted treatment redundant. These patients were therefore excluded from the
analyses.
Patient characteristics are shown in Table 1, along with the characteristics after multiple
imputation. The distribution of patients according to the MSKCC risk score showed a high
proportion of patients (55%) with a poor prognosis. 42% of the patients had an intermediate
prognosis. Since all patients presented with metastatic disease, very few patients (3%) had a
favourable prognosis (e.g., 86% of the patients had a time from diagnosis to treatment, which
is one of the MSKCC criteria, of less than one year).
Fifty-four percent (336/621) of all patients was treated with targeted therapies. Of these
patients, 84% (282/336) received sunitinib as first-line therapy. Other first-line treatments
given were temsirolimus (7%, 24/336) and sorafenib (3%, 11/336). 101 patients also received a
second-line therapy; the majority was treated with everolimus (40%, 40/101) or sorafenib
(28%, 28/101). Median overall survival (OS) of patients treated with targeted therapies was
12.6 months (95% C.I. 10.5–14.8).
A cost-effectiveness analysis in metastatic renal cell carcinoma
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Table 1. Patient and disease characteristics before start of first- and second-line treatment.
First-line Second-line
Real world-data
(N = 621)
Average of imputed datasets
(N = 621)
Real world-data
(N = 101)
Average of imputed datasets
(N = 101)
Sex—N (%)
Female 213 (34%) 213 (34%) 27 (27%) 27 (27%)
Male 408 (66%) 408 (66%) 74 (73%) 74 (73%)
Median age—yr (range) 66 (23–93) 66 (23–93) 62 (23–79) 62 (23–79)
Histology—N (%)
Clear cell 354 (57%) 354 (57%) 69 (68%) 69 (68%)
Other * 267 (43%) 267 (43%) 32 (32%) 32 (32%)
WHO performance status—N
(%)
0–1 204 (33%) 430 (69%) 34 (34%) 73 (72%)
2–4 61 (10%) 191 (31%) 9 (9%) 28 (28%)
Missing 356 (57%) 58 (57%)
Site of metastasis—N (%)
one 195 (31%) 206 (33%) 19 (19%) 19 (19%)
more than one 398 (64%) 415 (67%) 82 (81%) 82 (81%)
Missing 28 (5%) 0 (0%)
Liver metastasis—N (%)
no 487 (78%) 509 (82%) 74 (73%) 74 (73%)
yes 106 (17%) 112 (18%) 27 (27%) 27 (27%)
Missing 28 (5%) 0 (0%)
Lung metastasis—N (%)
no 163 (26%) 173 (28%) 21 (21%) 21 (21%)
yes 430 (69%) 448 (72%) 80 (79%) 80 (79%)
Missing 28 (5%) 0 (0%)
Bone metastasis—N (%)
no 375 (60%) 393 (63%) 58 (57%) 58 (57%)
yes 218 (35%) 228 (37%) 43 (43%) 43 (43%)
Missing 28 (5%) 0 (0%)
Brain metastasis—N (%)
no 546 (88%) 571 (92%) 92 (91%) 92 (91%)
yes 47 (8%) 50 (8%) 9 (9%) 9 (9%)
Missing 28 (5%) 0 (0%)
Prior nephrectomy—N (%)
no 452 (73%) 453 (73%) 43 (43%) 43 (43%)
yes 168 (27%) 168 (27%) 58 (57%) 58 (57%)
Missing 1 (0%) 0 (0.0%)
Haemoglobin—N (%)
normal 171 (28%) 205 (33%) 20 (20%) 20 (20%)
< LLN 347 (56%) 416 (67%) 78 (77%) 81 (80%)
Missing 103 (17%) 3 (3%)
Neutrophil count—N (%)
normal 203 (33%) 383 (62%) 67 (66%) 88 (87%)
> ULN 108 (17%) 238 (38%) 10 (10%) 13 (13%)
Missing 310 (50%) 24 (24%)
Platelet count—N (%)
normal 358 (58%) 452 (73%) 66 (65%) 70 (69%)
(Continued )
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Almost half (46%, 285/621) of all patients did not receive any targeted therapy. Of these 285
patients, 69 patients (24%) fulfilled the SUTENT trial eligibility criteria. Most patients (76%)
did not fulfill the SUTENT trial eligibility criteria; 168 patients (78%) did not have a clear-cell
subtype, 46 patients (21%) did not have a WHO performance status of 0 or 1 and 2 patients
(1%) had brain metastases. Median OS of patients not treated with targeted therapies was
2.6 months (95% C.I. 2.1–3.5); 10.6 months (95% C.I. 3.8–18.6) for patients fulfilling the
SUTENT trial eligibility criteria and 1.9 months (95% C.I. 1.6–2.6) for patients not fulfilling
the SUTENT trial eligibility criteria.
Table 2 shows the final models with their covariates (e.g., patient and disease characteris-
tics) and corresponding coefficients to estimate TTE1, the type of event after TTE1 and TTE2.
For example, a WHO performance status of 2–4 means a shorter TTE1.
Internal validation
Observed data from the PERCEPTION registry showed a median OS of 7.3 months (0.6 LYs)
(95% C.I. 6.3–8.4) for the total population (in which 54% of the patients received a targeted
therapy). Median OS in the model was 7.0 months (0.6 LYs) (95% C.I. 5.7–8.3) if patients were
treated as they were in the real world (i.e., base-case scenario). The OS derived from the PER-
CEPTION registry fell within the 95% C.I. of the outcome of the model. Additionally, the
observed Kaplan Meier curves (TTE1, TTE2 and OS) were closely followed by the survival
curves derived from the model (S3–S5 Figs).
Table 1. (Continued)
First-line Second-line
Real world-data
(N = 621)
Average of imputed datasets
(N = 621)
Real world-data
(N = 101)
Average of imputed datasets
(N = 101)
> ULN 140 (23%) 169 (27%) 29 (29%) 31 (31%)
Missing 123 (20%) 6 (6%)
Albumin—N (%)
normal 247 (40%) 391 (63%) 51 (51%) 75 (74%)
< LLN 136 (22%) 230 (37%) 18 (18%) 26 (26%)
Missing 238 (38%) 32 (32%)
Corrected serum calcium—N
(%)
normal 243 (39%) 421 (68%) 45 (45%) 72 (71%)
> ULN 116 (19%) 200 (32%) 18 (18%) 29 (29%)
Missing 262 (42%) 38 (38%)
Alkaline phosphatase—N (%)
normal 324 (52%) 432 (70%) 65 (64%) 74 (73%)
> ULN 139 (22%) 189 (30%) 24 (24%) 27 (27%)
Missing 158 (25%) 13 (13%)
Lactate dehydrogenase—N
(%)
normal 277 (45%) 372 (60%) 63 (62%) 71 (70%)
> 1.5 times ULN 174 (28%) 249 (40%) 28 (28%) 30 (30%)
Missing 170 (27%) 10 (10%)
Abbreviations: LLN, lower limit of normal; ULN, upper limit of normal.
* mRCC was clinically established without histopathological confirmation in 17% of patients and mRCC was classified as not otherwise specified without
further subtyping in 13% of patients. It is likely that a substantial proportion of these patients had a clear cell subtype.
https://doi.org/10.1371/journal.pone.0177364.t001
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Effectiveness
The model yielded an estimated mean survival of 1.2 LYs (14.4 months) if patients were treated
as they were in the real world (in which 54% of the patients received a targeted therapy). If all
treatment-eligible patients would be treated with first-line sunitinib followed by sorafenib, ever-
olimus or another second-line treatment (if they did not die after first-line treatment), mean
survival would increase to 1.3 LYs (15.6 months). If none of the patients were to be treated with
any targeted therapy, mean survival would decrease to 0.9 LYs (10.8 months) (Table 3).
If patients were treated as they were in the real world, mean QALYs are 0.807. If all treat-
ment-eligible patients would be treated with first-line sunitinib followed by sorafenib, everoli-
mus or another second-line treatment, mean QALYs would increase to 0.883, 0.868 or 0.841
respectively. If none of the patients were to be treated with any targeted therapy, mean QALYs
would decrease to 0.576 (Table 3).
Costs
Mean total costs per treatment strategy are presented in Table 3. Mean total costs per patient
amount to €58,912 if patients were treated as they were in the real world. If all treatment-
Table 2. Covariates and corresponding coefficients of the survival models and logistic regression model.
Time to event 1
(first 12 months)
Time to event 1
(> 12 months)
Type of event 1* Time to event 2
Model type Loglogistic Exponential Logistic Weibull
Covariate Coefficient (s.e.) Coefficient (s.e.) Coefficient (s.e.) Coefficient (s.e.)
Constant 1.060 (0.393) 5.227 (0.663) -1.778 (0.790) 2.804 (0.249)
Age (yr) 0.012 (0.005) -0.027 (0.009) 0.037 (0.013)
Sex (male vs. female) -0.382 (0.185)
Histology (non-clear cell vs. clear cell) -0.229 (0.112)
Prior nephrectomy (yes vs. no) 0.783 (0.130)
Number of metastatic sites (more than 1 vs. 1) -0.306 (0.120) -0.387 (0.199)
WHO performance status (2–4 vs. 0–1) -0.585 (0.136)
Liver metastases (yes vs. no) -0.459 (0.137) 0.632 (0.164)
Bone metastases (yes vs. no) 0.277 (0.113) -0.330 (0.170) -0.421 (0.150)
Brain metastases (yes vs. no) -0.657 (0.238)
Thrombocytes (>ULN vs. normal) 0.587 (0.320) -0.360 (0.183)
Neutrophil count (>ULN vs. normal) -0.258 (0.136)
Albumin (<LLN vs. normal) -0.290 (0.137) 1.074 (0.381) -0.388 (0.196)
Alkaline phosphatase (>ULN vs. normal) -0.269 (0.129)
First-line sunitinib (vs. no targeted therapy) 0.915 (0.124) -0.602 (0.201)
First-line temsirolimus (vs. no targeted therapy) 0.580 (0.244) -1.529 (0.611)
First-line other (vs. no targeted therapy) 0.992 (0.273) 0.339 (0.375)
Second-line everolimus (vs. sorafenib) -0.143 (0.191)
Second-line other (vs. sorafenib) -0.388 (0.181)
TTE 1 (TTE 1 > 12 months vs. TTE 1 < = 12 months) -0.641 (0.270) 0.537 (0.147)
Shape parameter 0.669 (0.028) 1.625 (0.137)
NOTE. Lung metastases, heamaglobin, corrected serum calcium and lactate dehydrogenase were considered for inclusion in the survival models and
logistic regression model, but excluded through backward and/or forward selection.
Abbreviations: LLN, lower limit of normal; ULN, upper limit of normal; TTE, time to event.
*0 = second-line therapy/ 1 = death.
https://doi.org/10.1371/journal.pone.0177364.t002
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eligible patients were to be treated with first-line sunitinib followed by sorafenib, everolimus
or another second-line treatment, mean total costs would increase to €65,984, €65,825 or
€65,062 respectively. If none of the patients would be treated with any targeted therapy, mean
total costs would decrease to €34,733.
Table 3. Summary of the cost-effectiveness results.
Real-world
treatment mix
No targeted
therapy
Real-world treatment mix
+ sunitinib for eligible
patients (followed by
sorafenib)
Real-world treatment mix
+ sunitinib for eligible
patients (followed by
everolimus)
Real-world treatment mix
+ sunitinib for eligible
patients (followed by other)
Per strategy
Time to event 1
(years)—mean
(95% CI)
1.1 (0.9–1.3) 0.9 (0.6–1.1) 1.1 (1.0–1.3) 1.1 (1.0–1.3) 1.1 (1.0–1.3)
Time to event 2
(years)—mean
(95% CI)*
0.7 (0.5–0.9) NA 0.9 (0.6–1.2) 0.8 (0.5–1.0) 0.6 (0.4–0.8)
LYs—mean (95%
CI)
1.2 (1.0–1.4) 0.9 (0.6–1.1) 1.3 (1.1–1.5) 1.3 (1.1–1.5) 1.3 (1.1–1.5)
QALYs—mean
(95% CI)
0.807 (0.647–
0.966)
0.576 (0.403–
0.749)
0.883 (0.719–1.046) 0.868 (0.709–1.027) 0.841 (0.687–0.996)
Total costs—mean
(95% CI)
€58,912
(€48,393–
€69,431)
€34,733
(€23,164–
€46,301)
€65,984 (€55,009–€76,959) €65,825 (€54,661–€76,989) €65,062 (€54,106–€76,018)
Compared to the
real-world
treatment mix
LYs gained—mean
(95% CI)
NA -0.4 (-0.6–-0.1) 0.1 (-0.1–0.3) 0.1 (-0.1–0.3) 0.1 (-0.1–0.2)
QALYs gained—
mean (95% CI)
NA -0.230 (-0.390–-
0.070)
0.076 (-0.056–0.208) 0.062 (-0.068–0.191) 0.035 (-0.094–0.163)
Incremental costs
—mean (95% CI)
NA -€24,179
(-€34,856–-
€13,502)
€7,072 (-€2,070–€16,214) €6,913 (-€2,252–€16,079) €6,150 (-€2,867–€15,167)
Cost/ LYG NA NR €60,716 €73,485 €117,814
Cost/ QALY NA NR €93,107 €111,972 €177,226
Compared to no
targeted therapy
LYs gained—mean
(95% CI)
0.4 (0.1–0.6) NA 0.5 (0.2–0.7) 0.4 (0.2–0.7) 0.4 (0.1–0.7)
QALYs gained—
mean (95% CI)
0.230 (0.070–
0.390)
NA 0.306 (0.126–0.486) 0.292 (0.114–0.470) 0.265 (0.088–0.442)
Incremental costs
—mean (95% CI)
€24,179
(€13,502–
€34,856)
NA €31,251 (€18,848–€43,654) €31,093 (€18,391–€43,794) €30,329 (€17,734–€42,924)
Cost/ LYG €69,068 NA €66,983 €70,003 €75,393
Cost/ QALY €105,011 NA €102,058 €106,483 €114,469
Note. Results are discounted (benefits 1.5% and costs 4%).
Abbreviations: LYs, life years; QALYs, quality-adjusted life years; LYG, life years gained; CI, confidence interval; NA, not applicable; NR, not reported.
* Time to event 2 is only relevant for patients who received a second-line therapy.
https://doi.org/10.1371/journal.pone.0177364.t003
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Cost-effectiveness
Compared to a scenario in which none of the patients receives a targeted therapy, the real-
world treatment mix results in a QALY gain of 0.230 and a cost increase of €24,179. Thus, an
additional €105,011 per QALY gained is spent compared to the scenario of not using targeted
therapy.
Compared to the real-world treatment mix, first-line sunitinib followed by sorafenib, evero-
limus or another second-line treatment leads to a QALY gain of 0.076, 0.062 and 0.035 at the
population level, respectively. When combined with the corresponding incremental costs (i.e.,
€7,072, €6,913 and €6,150), the incremental costs per QALY gained are €93,107, €111,972
and 177,226, respectively (Table 3). Note that the health gains are achieved by changing the
treatment of a relatively small group of patients representing 11% of the population. These are
patients who were eligible to receive sunitinib but did not receive it in real life; in this group,
sunitinib leads to a gain of 0.684, 0.558 or 0.315 QALYs per patient.
Sensitivity analyses
The tornado diagram (Fig 2) shows the variability in the ICER of sunitinib followed by everoli-
mus compared to the real-world treatment mix as a consequence of changes in the values of
various input parameters. Varying the unit costs of first-line sunitinib has the highest impact
on the ICER.
Fig 3 shows the uncertainty around the total costs and QALYs as obtained from the PSA.
For sunitinib followed by sorafenib, everolimus or another second-line treatment, 88.3%,
82.3% and 72.1% of all simulations fell in the north-east quadrant indicating more QALYs and
higher costs compared to the real-world treatment mix. For the scenario in which none of the
Fig 2. Results of the univariate sensitivity analyses.
https://doi.org/10.1371/journal.pone.0177364.g002
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patients received a targeted therapy, 99.4% of all simulations fell in the south-west quadrant
indicating less QALYs and lower costs.
Cost-effectiveness acceptability curves are presented in Fig 4, showing the likelihood that
treatment strategies would be cost-effective at a given willingness-to-pay threshold. Treating
according to the real-world treatment mix never attains more than 16% of simulations. Treat-
ing all patients with sunitinib followed by sorafenib or everolimus would be favoured; these
scenarios have a probability of 34% and 15%, respectively, of being cost-effective at a willing-
ness-to-pay threshold of €106,000. Not treating any patient with a targeted therapy would be
preferred at willingness-to-pay thresholds below €106,000, but this scenario results in health
loss.
Discussion
To the best of our knowledge, this is the first study that models the full disease course of
patients with mRCC using real-world data. We found that real-world treatment of mRCC
patients yields a QALY gain of 0.230 with incremental costs of €24,179 compared to a scenario
in which none of the patients would receive a targeted therapy. Thus, we currently pay
€105,011 per QALY gained. However, only 54% of the patients in our study population
received a targeted therapy and this raises the question about what the potential impact would
be if all treatment-eligible patients were to receive targeted therapy. Compared to real-world
treatment, health can be gained if all eligible patients were to be treated with first-line sunitinib
followed by sorafenib or everolimus. The costs to gain health by treating all eligible patients
with these treatment strategies, i.e., €93,107 and €111,972 per QALY gained, respectively, are
Fig 3. Cost-effectiveness plane for various treatment scenarios versus real-world treatment mix.
https://doi.org/10.1371/journal.pone.0177364.g003
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similar to the current costs per QALY gained. These costs include the costs of both first- and
second-line therapy.
The proportion of patients not being treated in this series is high at 46% (285/621). How-
ever, not all these patients were eligible for targeted therapy. We found that one in four
patients (69/268; 26%) fulfilling SUTENT trial eligibility criteria did not receive any targeted
therapy. Also in England, one in three patients with mRCC eligible for either sunitinib or
pazopanib did not receive the drug.[10] Previous analyses indicated that patients aged
65+ years were less likely to receive targeted therapy than younger patients after adjustment
for other factors.[9] However, the exact causes underlying the remarkably high proportion of
non-treated patients deserve further study. Importantly, all drugs studied in this project were
available in the Netherlands during the study period without any limitations for patients or
prescribers, so this could not explain why many eligible patients in Dutch daily clinical practice
did not receive targeted therapy.
Multiple economic evaluations of targeted therapies in mRCC have been published using
data from RCTs, two of which examined the cost-effectiveness of sunitinib.[23–27] Several
explanations exist for differences regarding the cost-effectiveness of sunitinib between our
study and these two studies (by Rema´k et al. and Benedict et al.).[23, 25] To start with, we used
real-world data (using the PERCEPTION registry) while the other studies used data from key
clinical trials. In addition, we looked at all patients with mRCC (at the initial presentation),
while the other two studies just studied one subgroup (i.e., sunitinib-eligible patients).
Some limitations to the data and methods deserve mentioning. First, since data from all
patients newly diagnosed with mRCC at the initial presentation in 42 hospitals (both general
Fig 4. Cost-effectiveness acceptability curves representing the probability that each treatment strategy is
cost-effective for a given maximum willingness-to-pay threshold per QALY gained.
https://doi.org/10.1371/journal.pone.0177364.g004
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and academic) were collected, it is likely that these patients are representative of average
patients with mRCC at initial diagnosis and the average treatment in The Netherlands. How-
ever, these patients account for only 40%-70% of the total mRCC population.[28] This total
population also includes patients who initially presented with non-metastatic disease and later
developed distant metastases. It is likely that a lot more of these patients are being treated; a
CEA based on these patients will likely yield different results.
Second, the model was populated using data from primary mRCC patients diagnosed
between January 2008 and December 2010 (i.e., treated between 2008 and 2013), whereas new
treatments have become available since then. The PERCEPTION registry also included a
cohort of (m)RCC patients diagnosed between January 2011 and June 2013, but since inclu-
sion criteria differed, patients were identified differently and the duration of follow-up varied,
it was not feasible to include these patients in the current study. Nevertheless, we did not
observe an increase in the proportion of patients receiving targeted therapies in this popula-
tion.[9] Therefore, we believe that the conclusion of this study still applies, and health can be
gained if more treatment-eligible patients receive targeted therapies.
Third, the alternative scenarios included in this model assume that all treatment-eligible
patients can be treated with a certain targeted therapy. This assumption may overestimate the
number of eligible patients since some of these patients eligible on the basis of the data cap-
tured in the PERCEPTION registry, may not actually be eligible because of poor organ func-
tion or comorbidities.
Fourth, treatment costs were overestimated somewhat since we did not adjust for dose
reductions. However, the effect on the incremental costs and ICERs will be minimal since the
treatment costs of 54% of the patients in the base-case real-world scenario were also overesti-
mated somewhat. Another limitation of this study is the amount of missing data in baseline
characteristics. Multiple imputations by chained equations were conducted to overcome this
problem.[13] This method ensures that all patients are included in the analysis but simulta-
neously guarantees that the uncertainties from missing data are retained.
In conclusion, RCTs have shown that targeted therapies like sunitinib are effective in
mRCC treatment. RCT-based cost-effectiveness analyses with a lifetime time horizon provide
important information about the cost-effectiveness of these therapies. However, these analyses
are limited in scope, since they are conducted in a selected population. A full disease model
and real-world data as presented here are essential in estimating cost-effectiveness ratios that
are externally valid. We found that one in four patients eligible for sunitinib did not receive it.
It is difficult to state with certainty why these patients did not receive sunitinib. One possible
reason is a limited health gain from treatment with sunitinib, but this reasoning seems unlikely
since we estimated that its use may add 0.684 QALYs (or eight months in perfect health) to
individual patients. Another possible reason is that it is not cost-effective to treat these patients.
However, we found that it is just as cost-effective to treat these patients with sunitinib as cur-
rent treatment practice.
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